RS59710B1 - Metod određivanja mutacionog statusa pik3ca u uzorku - Google Patents

Metod određivanja mutacionog statusa pik3ca u uzorku

Info

Publication number
RS59710B1
RS59710B1 RS20191668A RSP20191668A RS59710B1 RS 59710 B1 RS59710 B1 RS 59710B1 RS 20191668 A RS20191668 A RS 20191668A RS P20191668 A RSP20191668 A RS P20191668A RS 59710 B1 RS59710 B1 RS 59710B1
Authority
RS
Serbia
Prior art keywords
sequence
dna
seq
pik3ca
mutant allele
Prior art date
Application number
RS20191668A
Other languages
English (en)
Serbian (sr)
Inventor
Evrykleia Lianidou
Athina Markou
Original Assignee
Pharmassist Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmassist Ltd filed Critical Pharmassist Ltd
Publication of RS59710B1 publication Critical patent/RS59710B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6858Allele-specific amplification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6816Hybridisation assays characterised by the detection means
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6853Nucleic acid amplification reactions using modified primers or templates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10Modifications characterised by
    • C12Q2525/186Modifications characterised by incorporating a non-extendable or blocking moiety
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2527/00Reactions demanding special reaction conditions
    • C12Q2527/107Temperature of melting, i.e. Tm
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
RS20191668A 2014-08-07 2015-07-28 Metod određivanja mutacionog statusa pik3ca u uzorku RS59710B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462034231P 2014-08-07 2014-08-07
PCT/GR2015/000036 WO2016020710A1 (en) 2014-08-07 2015-07-28 Method of determining pik3ca mutational status in a sample
EP15753745.7A EP3198026B1 (en) 2014-08-07 2015-07-28 Method of determining pik3ca mutational status in a sample

Publications (1)

Publication Number Publication Date
RS59710B1 true RS59710B1 (sr) 2020-01-31

Family

ID=53938365

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20191668A RS59710B1 (sr) 2014-08-07 2015-07-28 Metod određivanja mutacionog statusa pik3ca u uzorku

Country Status (18)

Country Link
US (1) US11279979B2 (OSRAM)
EP (1) EP3198026B1 (OSRAM)
JP (1) JP6770957B2 (OSRAM)
CN (1) CN106715723B (OSRAM)
CA (1) CA2957396C (OSRAM)
CY (1) CY1122647T1 (OSRAM)
DK (1) DK3198026T3 (OSRAM)
ES (1) ES2764423T3 (OSRAM)
HR (1) HRP20192353T1 (OSRAM)
HU (1) HUE047958T2 (OSRAM)
IL (1) IL250392B (OSRAM)
LT (1) LT3198026T (OSRAM)
PL (1) PL3198026T3 (OSRAM)
PT (1) PT3198026T (OSRAM)
RS (1) RS59710B1 (OSRAM)
SI (1) SI3198026T1 (OSRAM)
SM (1) SMT202000005T1 (OSRAM)
WO (1) WO2016020710A1 (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3023788T3 (da) 2010-05-14 2020-04-27 Massachusetts Gen Hospital Sammensætninger af tumorspecifikke neoantigener til anvendelse ved behandling af tumorer
WO2015039024A1 (en) 2013-09-16 2015-03-19 Oregon Health & Science University Bioabsorbable clips and applicator for tissue closure
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
CA2934073A1 (en) 2013-12-20 2015-06-25 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
US9883866B2 (en) 2014-11-03 2018-02-06 Oregon Health & Science University Clips and applicator for tissue closure
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
ES3049406T3 (en) * 2014-12-19 2025-12-16 Broad Inst Inc Methods for profiling the t-cell-receptor repertoire
PE20180670A1 (es) 2015-05-20 2018-04-19 Broad Inst Inc Neoantigenos compartidos
US10870891B2 (en) 2017-01-05 2020-12-22 Biodesix, Inc. Diagnostic test system for specific, sensitive and reproducible detection of circulating nucleic acids in whole blood
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CN118370809A (zh) 2017-04-03 2024-07-23 百欧恩泰美国公司 蛋白质抗原及其用途
CN107287309A (zh) * 2017-07-06 2017-10-24 罗保君 一种血液循环肿瘤dna点突变检测方法
JP6603827B2 (ja) * 2017-07-26 2019-11-06 積水メディカル株式会社 変異遺伝子検出方法
CN109295175A (zh) * 2017-09-08 2019-02-01 广州健天基因技术有限公司 用于检测人胃肠道间质瘤c-kit基因v559a突变的引物、检测方法及试剂盒
CN109306374A (zh) * 2017-09-08 2019-02-05 广州健天基因技术有限公司 用于检测人类pik3ca基因e545k突变的引物、检测方法及试剂盒
JP7306618B2 (ja) * 2017-09-26 2023-07-11 東ソー株式会社 がんの転移形成能に関与する因子および前記因子を用いたがん患者の予後予測方法
WO2019126186A1 (en) 2017-12-18 2019-06-27 Neon Therapeutics, Inc. Neoantigens and uses thereof
CN107937490A (zh) * 2018-01-15 2018-04-20 福建农林大学 一种非对称pcr的试纸条检测植物病原菌的方法及试剂盒
WO2019155050A1 (en) * 2018-02-12 2019-08-15 F. Hoffmann-La Roche Ag Method of predicting response to therapy by assessing tumor genetic heterogeneity
JP7534962B2 (ja) 2018-06-19 2024-08-15 ビオンテック ユーエス インコーポレイテッド ネオ抗原およびその使用
CN109666747A (zh) * 2019-02-20 2019-04-23 天津脉络医学检验有限公司 一种引物探针组合物及其应用
US11812966B2 (en) 2020-04-24 2023-11-14 NeuraMedica Inc. Clips, appliers, and cartridges
CN113930500B (zh) * 2020-07-13 2024-11-19 铭炽生物科技(上海)有限公司 人pik3ca基因突变的数字pcr检测方法及应用
CN112951325B (zh) * 2021-02-18 2023-04-21 北京吉因加医学检验实验室有限公司 一种用于癌症检测的探针组合的设计方法及其应用
CN113063835B (zh) * 2021-03-19 2022-08-02 中山大学 一种基于元素标记-电感耦合等离子体质谱检测策略的cfDNA分析方法及其应用
WO2023025218A1 (zh) * 2021-08-25 2023-03-02 南京金斯瑞生物科技有限公司 一种用于检测单碱基突变的引物组和基因芯片方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3296407T1 (sl) 2004-03-02 2019-09-30 The Johns Hopkins University Mutacije gena PIK3CA pri rakih pri ljudeh
SG10201506658TA (en) * 2007-02-26 2015-09-29 Wayne John Cancer Inst Utility of b-raf dna mutation in diagnosis and treatment of cancer
US8071338B2 (en) * 2007-08-08 2011-12-06 Roche Molecular Systems, Inc. Suppression of amplification using an oligonucleotide and a polymerase significantly lacking 5′-3′ nuclease activity
GB2453173A (en) * 2007-09-28 2009-04-01 Dxs Ltd Polynucleotide primers
US20100041048A1 (en) * 2008-07-31 2010-02-18 The Johns Hopkins University Circulating Mutant DNA to Assess Tumor Dynamics
CN101445832B (zh) * 2008-12-23 2011-09-14 广州益善生物技术有限公司 Pik3ca基因突变的检测探针、液相芯片及其检测方法
CN102234685B (zh) * 2010-04-23 2014-08-27 益善生物技术股份有限公司 一种pik3ca基因突变检测液相芯片
WO2012075231A1 (en) * 2010-12-03 2012-06-07 Brandeis University Methods and kits for detecting nucleic acid mutants in wild-type populations
CN102533958A (zh) 2010-12-28 2012-07-04 苏州科贝生物技术有限公司 一种检测人pik3ca基因突变的方法和试剂盒
EP2663652B1 (en) * 2011-01-11 2018-11-14 Roche Diagniostics GmbH High resolution melting analysis as a prescreening tool
WO2012131092A2 (en) * 2011-03-31 2012-10-04 Signature Diagnostics Ag Method and kits for the prediction of response/nonresponse to the treatment with an anti-egfr antibody in patients with colorectal cancer of all uicc stages
CN103635593B (zh) * 2011-05-04 2018-03-20 生物概念股份有限公司 用于检测核酸序列变体的方法
SG2014010276A (en) 2011-08-18 2014-03-28 Nestec Sa Compositions and methods for detecting allelic variants
JP2013081450A (ja) 2011-09-27 2013-05-09 Arkray Inc 多型検出用プローブ、多型検出方法、薬効判定方法及び多型検出用試薬キット
US11261494B2 (en) * 2012-06-21 2022-03-01 The Chinese University Of Hong Kong Method of measuring a fractional concentration of tumor DNA
EP2711432A1 (en) * 2012-09-21 2014-03-26 Genomica S.A.U. Method for detection of BRAF and PI3K mutations
EP3666903B1 (en) * 2013-08-12 2025-12-31 Bio-Rad Laboratories, Inc. AMPLIFICATION REPORTER GENE CONTAINING OLIGOMERS WITH BASIC PAIRINGS

Also Published As

Publication number Publication date
EP3198026A1 (en) 2017-08-02
CY1122647T1 (el) 2021-03-12
EP3198026B1 (en) 2019-10-09
JP6770957B2 (ja) 2020-10-21
SMT202000005T1 (it) 2020-03-13
US11279979B2 (en) 2022-03-22
PL3198026T3 (pl) 2020-05-18
IL250392B (en) 2020-03-31
ES2764423T3 (es) 2020-06-03
LT3198026T (lt) 2020-01-27
CN106715723A (zh) 2017-05-24
HRP20192353T1 (hr) 2020-03-20
CN106715723B (zh) 2021-03-30
US20170233821A1 (en) 2017-08-17
DK3198026T3 (da) 2020-01-20
CA2957396C (en) 2021-03-09
WO2016020710A1 (en) 2016-02-11
JP2017523810A (ja) 2017-08-24
HUE047958T2 (hu) 2020-05-28
SI3198026T1 (sl) 2020-02-28
CA2957396A1 (en) 2016-02-11
PT3198026T (pt) 2020-01-16
IL250392A0 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
EP3198026B1 (en) Method of determining pik3ca mutational status in a sample
US12270081B2 (en) Method for quantification of PD-L1 expression
AU2022228167B2 (en) Methods and materials for assessing loss of heterozygosity
Voutsina et al. Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer
JP2012501652A (ja) 悪性神経膠腫におけるイソクエン酸デヒドロゲナーゼ遺伝子および他の遺伝子の遺伝子変化
CN107949642A (zh) 用于筛选实体瘤的组合物和方法
CA3198134A1 (en) Immunotherapy response signature
US12391985B2 (en) Method of determining PIK3CA mutational status in a sample
EP2783015A1 (en) Responsiveness to angiogenesis inhibitors
Palande et al. A liquid biopsy platform for detecting gene-gene fusions as glioma diagnostic biomarkers and drug targets
US20250129428A1 (en) Methods and materials for predicting the progression of prostate cancer and treating same
HK1241934A1 (en) Method of determining pik3ca mutational status in a sample
HK1241934B (en) Method of determining pik3ca mutational status in a sample
Anandappa Developing biomarker guided treatments for colorectal cancer
Richter-Pechańska A novel approach to develop predictive biomarkers: prediction of response to anti-EGFR therapy in a large panel of patient-derived colorectal cancer xenograft models
Pechanska A novel approach to develop predictive biomarkers
HK1197755A (en) Responsiveness to angiogenesis inhibitors